- Question from Maura: When will PARP inhibitors be available and will they be allowed for use following adjuvant therapy for triple-negative breast cancer?
- Answers - Eric Winer, M.D. Good question. The availability of the PARP inhibitors will depend upon a study which has been completed but from which we have no data yet. If that study shows a benefit for the PARP inhibitor, it could be available before the end of 2011. It is not going to be recommended for use as part of adjuvant therapy since that will require additional clinical trials over the next few years. If the PARP inhibitors become commercially available, there will be clinical trials in the adjuvant setting but these will be studies where some women get the PARP inhibitors and some don't. There are serious side effects associated with PARP inhibitors, which is why we have to be very careful in evaluating these agents before we apply them to routine clinical use in patients with early-stage breast cancer.
The Ask-the-Expert Online Conference called Updates From the 2010 San Antonio Breast Cancer Symposium featured Eric Winer, M.D. and Marisa Weiss, M.D. answering your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
Editor's Note: This conference took place in December 2010.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.